In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Background: The prevalence of heart failure with mildly reduced or preserved ejection
fraction markedly increases with age, with older individuals disproportionately facing excess …

Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …

Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …

Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce mortality/morbidity in heart
failure (HF). We explored the implementation of SGLT2i over time, and patient …

This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …